Reopro (Abciximab) - Summary

REOPRO SUMMARY

Abciximab, ReoPro®, is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin ((alpha) _v(beta)₃) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications.

• in patients undergoing percutaneous coronary intervention
• in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours

Safety and efficacy ofAbciximab use in patients not undergoing percutaneous coronary intervention have not beenestablished.

Abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in CLINICAL STUDIES.

REOPRO NEWS HIGHLIGHTS

Published Studies Related to Reopro (Abciximab)

One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) Study. [2008.07]

Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes. [2008.05.01]

Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. [2008.04.16]

Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. [2008.02.16]

Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). [2008.01]

more>>

Clinical Trials Related to Reopro (Abciximab)

A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) [Completed]

ReoPro and Retavase to Treat Acute Stroke [Active, not recruiting]

ReoPro and Retavase to Restore Brain Blood Flow After Stroke [Active, not recruiting]

FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab [Completed]

A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab [Completed]

more>>